In short
Clinical trials are studying HYDROGEN PEROXIDE as one of several oral antiseptics in patients with respiratory infections. These trials aim to measure immediate virucidal activity, how long the effect lasts, and changes in saliva virus levels in people with COVID-19, influenza A, or RSV.
Key points
- Clinical trials are studying HYDROGEN PEROXIDE as an oral antiseptic in people with respiratory infections. The trial includes patients with COVID-19, influenza A, or RSV. It is a Phase 3 interventional study with a planned enrollment of 810 participants. Researchers are measuring viral load in saliva and a D/T ratio to estimate intact virus particles. The study also checks how long the effect lasts after a single rinse, up to 7 hours.
Trial overview
The available trial is a clinical study of HYDROGEN PEROXIDE used as one of several oral antiseptics for people with respiratory infections. The study is looking at the immediate virucidal activity in saliva after a single mouth rinse and how long that effect lasts, up to 7 hours after use.
Who can participate
This study includes patients diagnosed with COVID-19, influenza A, or RSV. These conditions are grouped in the trial as respiratory diseases, which means illnesses that affect breathing and the airways.
The trial does not provide more detailed entry rules in the source data, so the main known target group is people already diagnosed with one of these respiratory infections.
What is being measured
The main outcome is viral load in saliva samples taken at different times after the mouthwashes are used. Viral load means the amount of virus found in the sample.
The study also measures the D/T ratio, which is described as a way to estimate the proportion of intact viral particles. In simple terms, this helps researchers estimate how much virus remains whole after treatment.
Researchers are checking these outcomes at different time points after application, including the period up to 7 hours later.
Trial design and phase
This is an interventional study, which means the research team gives a treatment and then measures the results. The trial is in Phase 3, which is a later stage that usually studies a treatment in a larger group of people.
The planned enrollment is 810 participants, showing that this is a fairly large study. The trial status is Authorised.
What the study may help show
This trial is designed to see whether HYDROGEN PEROXIDE, used in the mouth, can quickly reduce virus levels in saliva in people with common respiratory infections. It also aims to show how long any effect lasts after one rinse.
Because the study compares different oral antiseptics, it may help researchers understand which rinse has the strongest immediate effect against respiratory viruses in the mouth.